Global Transplant Diagnostics Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143047
- Pages: 225
-
Format:
Short Description
Global Transplant Diagnostics Market, By Product Type (Transplant Diagnostic Instrument, Transplant Diagnostic Software, Transplant Diagnostic Reagent), Technology (PCR-Based Molecular Assays, Sequencing-Based Molecular Assays), Transplant Type (Solid Organ Transplantation, Stem Cell Transplantation, Soft Tissue Transplantation, Bone Marrow Transplantation, Other Transplants), Application (Diagnostic Applications, Research Applications), End User (Research Laboratories and Academic Institutes, Hospital and Transplant Centers, Commercial Service Providers, Others), Distribution Channel (Direct Tender, Retail Sales, Others), Country (U.S., Canada, Mexico, Germany, France, the U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and the Rest of Europe, China, Japan, India, South Korea, Singapore, Thailand, Malaysia, Australia, Philippines, Indonesia, and the Rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Egypt, Israel, and the Rest of the Middle East and Africa) Industry Trends and Forecast to 2029
Market Definition
Transplant diagnostics are the immunogenetics and histocompatibility of organ and hematopoietic stem cell transplantations. These diagnostics help healthcare professionals determine compatibility between potential recipients and organ donors. These are used in various disciplines, such as immunogenetics, pathology, and infectious diseases, among others. Transplant diagnostics are used to determine whether the donor and the recipient of the organ are compatible before or after the transplant. With the introduction of transplant diagnostics, the prevalence of diseases that can cause organ failure, including both pre-and post-transplant screening, is expected to explode. The market has attracted the interest of healthcare professionals due to the many advantages these tests offer to verify suitability for a transplant procedure. Organ transplantation is one of the most popular treatment options for many end-stage renal disease patients on continuous dialysis.
In addition, it is possible to investigate organ transplantation for cases involving the heart, liver, or bone marrow. Although in many cases, there is a strong association between renal failure and liver transplantation, including end-stage renal disease. New transcriptomic, proteomic, and genomic indicators in molecular diagnostics can help to better tailor transplant therapy and early detection of rejection events. Also, strategic initiatives by market players, technological progressions in transplant diagnostics, high sterility assurance, and increasing investment in healthcare infrastructure increase the demand for transplant diagnostics.
Market Segmentation
The global transplant diagnostics market is segmented into six notable segments based on product type, technology, transplant type, application, end user, and distribution channel.
On the basis of product type, the global transplant diagnostics market is segmented into transplant diagnostic instrument, transplant diagnostic software, transplant diagnostic reagent
On the basis of technology, the global transplant diagnostics market is segmented into PCR-based molecular assays, and sequencing-based molecular assays
On the basis of transplant type, the global transplant diagnostics market is segmented into solid organ transplantation, stem cell transplantation, soft tissue transplantation, bone marrow transplantation, and other transplants
On the basis of application, the global transplant diagnostics market is segmented into diagnostic applications and research applications
On the basis of end user, the global transplant diagnostics market is segmented into research laboratories and academic institutes, hospitals and transplant centers, commercial service providers, and others
On the basis of distribution channel, the global transplant diagnostics market is segmented into direct tender, retail sales, and others
Market Players
Some of the major players operating in the global transplant diagnostics market are:
Hologic, Inc.
Biofortuna Limited
Takara Bio Inc.
Abbott
Diagnstica Longwood SL
Adaptive Biotechnologies
NanoString
Arquer Diagnostics Ltd
altona Diagnostics GmbH
ELITechGroup
DiaSorin S.p.A.
Horiba Ltd
EUROFINS VIRACOR
CareDx Inc.
Laboratory Corporation of America Holdings.
Randox Laboratories Ltd.
Thermo Fisher Scientific Inc.
Preservation Solutions, Inc.
TransMedics
Transonic
Stryker
Bio-Rad Laboratories, Inc.
Zimmer Biomet
QIAGEN
F. Hoffmann-La Roche Ltd
BIOMRIEUX
Illumina, Inc.
Luminex Corporation (A subsidiary of DiaSorin Company)
IMMUCOR
CLONIT srl
PathoNostics
Biotype GmbH
BAG Diagnostics GmbH
TABLE OF CONTENTS
1 INTRODUCTION 75
1.1 OBJECTIVES OF THE STUDY 75
1.2 MARKET DEFINITION 75
1.3 OVERVIEW OF THE GLOBAL TRANSPLANT DIAGNOSTICS MARKET 75
1.4 CURRENCY AND PRICING 78
1.5 LIMITATIONS 78
1.6 MARKETS COVERED 78
2 MARKET SEGMENTATION 84
2.1 MARKETS COVERED 84
2.2 GEOGRAPHICAL SCOPE 85
2.3 YEARS CONSIDERED FOR THE STUDY 86
2.4 DBMR TRIPOD DATA VALIDATION MODEL 87
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 90
2.6 MULTIVARIATE MODELLING 91
2.7 MARKET APPLICATION COVERAGE GRID 92
2.8 SOURCE LIFELINE CURVE 93
2.9 DBMR MARKET POSITION GRID 94
2.10 VENDOR SHARE ANALYSIS 95
2.11 SECONDARY SOURCES 96
2.12 ASSUMPTIONS 96
3 EXECUTIVE SUMMARY 97
3.1 EPIDEMOLOGY 103
3.2 PESTEL_ANALYSIS 118
3.3 PORTER'S FIVE FORCE 119
3.4 TECHNOLOGICAL INNOVATIONS 120
4 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: REGULATIONS 121
5 KEY STRATEGIC INITIATIVES 125
6 INDUSTRIAL INSIGHTS: 126
7 MARKET OVERVIEW 128
7.1 DRIVERS 130
7.1.1 RISING NUMBER OF TRANSPLANT PROCEDURES 130
7.1.2 INCREASE IN THE TECHNOLOGICAL ADVANCEMENTS IN THE FIELD OF TRANSPLANTS 130
7.1.3 RISING HEALTHCARE SPENDING 130
7.1.4 ADOPTION OF CROSS-MATCHING AND CHIMERISM TESTING DURING PRE- AND POST-TRANSPLANTATION 131
7.2 RESTRAINTS 131
7.2.1 HIGH COST OF ORGAN TRANSPLANTATION 131
7.2.2 THE RISKS AND DIFFICULTIES OF ORGAN TRANSPLANTATION 131
7.3 OPPORTUNITIES 132
7.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 132
7.3.2 RISE IN PUBLIC, PRIVATE, AND GOVERNMENT FUNDING FOR ORGAN TRANSPLANTATION 132
7.3.3 SURGE IN AWARENESS ABOUT THE IMPORTANCE OF ORGAN TRANSPLANTATION 133
7.4 CHALLENGES 134
7.4.1 ETHICAL CHALLENGES FACED DURING ORGAN TRANSPLANTATION 134
7.4.2 LACK OF ORGAN DONORS OR GAP BETWEEN ORGAN DONORS AND ORGANS NEEDED ANNUALLY 134
8 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT TYPE 136
8.1 OVERVIEW 137
8.2 TRANSPLANT DIAGNOSTIC INSTRUMENTS 140
8.2.1 AUTOMATED PIPETTORS & DISPENSERS 140
8.2.2 AUTOMATED SYSTEMS 140
8.2.2.1 NUCLEIC ACID EXTRACTION SYSTEM 141
8.2.2.2 PCR SETUP 141
8.2.2.3 OTHERS 141
8.2.3 NGS INSTRUMENTS 141
8.2.4 READERS & ANALYZERS 141
8.2.5 TRANSPLANT DIAGNOSTIC KITS 141
8.2.5.1 ASPERGILLUS SPP KITS 142
8.2.5.2 P. JIROVECII KITS 142
8.2.5.3 CMV KITS 142
8.2.5.4 EBV KITS 142
8.2.5.5 BKV KITS 143
8.2.5.6 VZV KITS 143
8.2.5.7 HSV1 KITS 143
8.2.5.8 HSV2 KITS 143
8.2.5.9 PARVOVIRUS B19 KITS 143
8.2.5.10 ADENOVIRUS KITS 143
8.2.5.11 ENTEROVIRUS KITS 143
8.2.5.12 JCV KITS 143
8.2.5.13 HHV6 KITS 143
8.2.5.14 HHV7 KITS 143
8.2.5.15 HHV8 KITS 143
8.2.5.16 TOXOPLASMA GONDII KITS 143
8.2.5.17 HEPATITIS E KITS 144
8.2.5.18 OTHER KITS 144
8.2.6 OTHER KITS 144
8.3 TRANSPLANT DIAGNOSTIC SOFTWARES 144
8.3.1 DNA SOFTWARE 145
8.3.2 NGS SOFTWARE 145
8.3.3 DATA MANAGEMENT SOFTWARE 145
8.3.4 OTHER SOFTWARES 145
8.4 TRANSPLANT DIAGNOSTIC REAGENTS 145
8.4.1 MONOCLONAL ANTIBODIES 146
8.4.2 CYTOTOXIC CONTROLS 146
8.4.3 HUMAN SERUM 146
8.4.4 OTHER REAGENTS 146
9 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY 147
9.1 OVERVIEW 148
9.2 PCR-BASED MOLECULAR ASSAYS 151
9.2.1 REAL TIME PCR 151
9.2.2 SEQUENCE-SPECIFIC PRIMER-PCR 151
9.2.3 SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR 152
9.2.4 RESTRICTION FRAGMENT LENGTH POLYMORPHISM (RFLP) 152
9.2.5 OTHER-PCR BASED MOLECULAR ASSAYS 152
9.3 SEQUENCING-BASED MOLECULAR ASSAYS 152
9.3.1 SANGER SEQUENCING 153
9.3.2 NEXT GENERATION SEQUENCING 153
9.3.3 OTHER SEQUENCING-BASED MOLECULAR ASSAYS. 153
10 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY TRANSPLANT TYPE 154
10.1 OVERVIEW 155
10.2 SOLID ORGAN TRANSPLANTATION 158
10.2.1 KIDNEY TRANSPLANTATION 158
10.2.2 LIVER TRANSPLANTATION 158
10.2.3 HEART TRANSPLANTATION 159
10.2.4 LUNG TRANSPLANTATION 159
10.2.5 PANCREAS TRANSPLANTATION 159
10.2.6 OTHER ORGAN TRANSPLANTATIONS 159
10.3 STEM CELL TRANSPLANTATION 159
10.3.1 BONE MARROW TRANSPLANT (BMT) 160
10.3.2 PERIPHERAL BLOOD STEM CELL TRANSPLANT 160
10.3.3 CORD BLOOD TRANSPLANT 160
10.3.4 OTHER STEM CELL TRANSPLANTS 160
10.4 SOFT TISSUE TRANSPLANTATION 160
10.4.1 SKIN GRAFT 161
10.4.2 CARTILAGE TRANSPLANTATION 161
10.4.3 ADRENAL AUTOGRAFTING 161
10.4.4 OTHER SOFT TISSUE TRANSPLANTATION. 161
10.5 BONE MARROW TRANSPLANTATION 162
10.5.1 AUTOLOGOUS BONE MARROW TRANSPLANT 162
10.5.2 ALLOGENEIC BONE MARROW TRANSPLANT 162
10.5.3 UMBILICAL CORD BLOOD TRANSPLANT. 163
10.6 OTHERS 163
11 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 164
11.1 OVERVIEW 165
11.2 DIAGNOSTIC APPLICATIONS 168
11.2.1 TRANSPLANT DIAGNOSTIC INSTRUMENT 168
11.2.1.1 AUTOMATED PIPETTORS & DISPENSERS 169
11.2.1.2 AUTOMATED SYSTEMS 169
11.2.1.3 NGS INSTRUMENTS 169
11.2.1.4 READERS & ANALYZERS 169
11.2.1.5 TRANSPLANT DIAGNOSTIC KITS 169
11.2.1.6 OTHERS 169
11.2.2 TRANSPLANT DIAGNOSTIC SOFTWARE 169
11.2.2.1 DNA SOFTWARE 170
11.2.2.2 NGS SOFTWARE 170
11.2.2.3 DATA MANAGEMENT SOFTWARE 170
11.2.2.4 OTHER SOFTWARES 170
11.2.3 TRANSPLANT DIAGNOSTIC REAGENT 170
11.2.3.1 MONOCLONAL ANTIBODIES 171
11.2.3.2 CYTOTOXIC CONTROLS 171
11.2.3.3 HUMAN SERUM 171
11.2.3.4 OTHER REAGENTS 171
11.3 RESEARCH APPLICATIONS 171
11.3.1 TRANSPLANT DIAGNOSTIC INSTRUMENT 172
11.3.1.1 AUTOMATED PIPETTORS & DISPENSERS 173
11.3.1.2 AUTOMATED SYSTEMS 173
11.3.1.3 NGS INSTRUMENTS 173
11.3.1.4 READERS & ANALYZERS 173
11.3.1.5 TRANSPLANT DIAGNOSTIC KITS 173
11.3.1.6 OTHERS 173
11.3.2 TRANSPLANT DIAGNOSTIC SOFTWARE 173
11.3.2.1 DNA SOFTWARE 174
11.3.2.2 NGS SOFTWARE 174
11.3.2.3 DATA MANAGEMENT SOFTWARE 174
11.3.2.4 OTHER SOFTWARES 174
11.3.3 TRANSPLANT DIAGNOSTIC REAGENT 174
11.3.3.1 MONOCLONAL ANTIBODIES 175
11.3.3.2 CYTOTOXIC CONTROLS 175
11.3.3.3 HUMAN SERUM 175
11.3.3.4 OTHER REAGENTS 175
12 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY END USER 176
12.1 OVERVIEW 177
12.2 HOSPITALS AND TRANSPLANT CENTERS 180
12.3 COMMERCIAL SERVICE PROVIDERS 180
12.4 RESEARCH LABORATORIES AND ACADEMIC INSTITUTES 180
12.5 OTHERS 181
13 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 182
13.1 OVERVIEW 183
13.2 DIRECT TENDER 186
13.3 RETAIL SALES 186
13.4 OTHERS 186
14 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY REGION 188
14.1 OVERVIEW 189
14.2 NORTH AMERICA 194
14.2.1 U.S. 206
14.2.2 CANADA 218
14.2.3 MEXICO 230
14.3 ASIA-PACIFIC 242
14.3.1 CHINA 256
14.3.2 JAPAN 268
14.3.3 SOUTH KOREA 280
14.3.4 INDIA 292
14.3.5 AUSTRALIA 304
14.3.6 SINGAPORE 316
14.3.7 THAILAND 328
14.3.8 MALAYSIA 340
14.3.9 INDONESIA 352
14.3.10 PHILIPPINES 364
14.3.11 REST OF ASIA-PACIFIC 376
14.4 EUROPE 377
14.4.1 GERMANY 392
14.4.2 FRANCE 404
14.4.3 U.K. 416
14.4.4 ITALY 428
14.4.5 RUSSIA 440
14.4.6 SPAIN 452
14.4.7 TURKEY 464
14.4.8 NETHERLANDS 476
14.4.9 SWITZERLAND 488
14.4.10 BELGIUM 500
14.4.11 REST OF EUROPE 512
14.5 SOUTH AMERICA 513
14.5.1 BRAZIL 525
14.5.2 ARGENTINA 537
14.5.3 REST OF SOUTH AMERICA 549
14.6 MIDDLE EAST & AFRICA 550
14.6.1 SOUTH AFRICA 563
14.6.2 SAUDI ARABIA 575
14.6.3 U.A.E 587
14.6.4 EGYPT 599
14.6.5 ISRAEL 611
14.6.6 REST OF MIDDLE EAST AND AFRICA 623
15 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: COMPANY LANDSCAPE 624
15.1 COMPANY SHARE ANALYSIS: GLOBAL 624
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 625
15.3 COMPANY SHARE ANALYSIS: EUROPE 626
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 627
16 SWOT ANALYSIS 628
17 COMPANY PROFILE 629
17.1 ABBOTT 629
17.1.1 COMPANY SNAPSHOT 629
17.1.2 REVENUE ANALYSIS 629
17.1.3 COMPANY SHARE ANALYSIS 630
17.1.4 PRODUCT PORTFOLIO 630
17.1.5 RECENT DEVELOPMENTS 630
17.2 THERMO FISHER SCIENTIFIC INC. 631
17.2.1 COMPANY SNAPSHOT 631
17.2.2 REVENUE ANALYSIS 631
17.2.3 COMPANY SHARE ANALYSIS 632
17.2.4 PRODUCT PORTFOLIO 632
17.2.5 RECENT DEVELOPMENTS 634
17.3 F. HOFFMANN LA ROCHE LTD 635
17.3.1 COMPANY SNAPSHOT 635
17.3.2 REVENUE ANALYSIS 635
17.3.3 COMPANY SHARE ANALYSIS 636
17.3.4 PRODUCT PORTFOLIO 636
17.3.5 RECENT DEVELOPMENT 637
17.4 TAKARA BIO INC. 638
17.4.1 COMPANY SNAPSHOT 638
17.4.2 REVENUE ANALYSIS 638
17.4.3 COMPANY SHARE ANALYSIS 639
17.4.4 PRODUCT PORTFOLIO 639
17.4.5 RECENT DEVELOPMENTS 639
17.5 HOLOGIC, INC 640
17.5.1 COMPANY SNAPSHOT 640
17.5.2 REVENUE ANALYSIS 640
17.5.3 COMPANY SHARE ANALYSIS 641
17.5.4 PRODUCT PORTFOLIO 641
17.5.5 RECENT DEVELOPMENTS 642
17.6 ADAPTIVE BIOTECHNOLOGIES 643
17.6.1 COMPANY SNAPSHOT 643
17.6.2 REVENUE ANALYSIS 643
17.6.3 PRODUCT PORTFOLIO 644
17.6.4 RECENT DEVELOPMENT 644
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
